戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  0.65 to 0.81]) as associated with H. pylori seroprevalence.
2 imilar results were observed for hotspots of seroprevalence.
3 the humoral immune response and to determine seroprevalence.
4 ce the observed relationship between age and seroprevalence.
5 ulate a pooled estimate of hepatitis D virus seroprevalence.
6 sociated herpesvirus (KSHV) has a restricted seroprevalence.
7 t, controlling for income per person and HIV seroprevalence.
8 r cCMV in countries with low to intermediate seroprevalence.
9 esults in a high post-vaccination poliovirus seroprevalence.
10  We previously reported an unexpectedly high seroprevalence (~10%) of N-methyl-D-aspartate-receptor s
11 S) 1988-1994 dataset found a relatively high seroprevalence (21%) of hepatitis E virus (HEV) infectio
12 ryzomys longicaudatus displaying the highest seroprevalence (5.9%), followed by Abrothrix longipilis
13  vs 0.7/1,000,000 person-years [p<0.01]) and seroprevalence (7.9 vs 3.3/100,000[p=0.04]) were also hi
14 ed an association between TLR1 and H. pylori seroprevalence, a finding that requires replication in n
15 es C Ad6 and Ad26 are being pursued as lower-seroprevalence Ad vectors but differ at the DNA level by
16 gene for IIIa capsid cement protein of lower-seroprevalence adenovirus serotype 6.
17 ation seroconverted due to infection and the seroprevalence after the wave rose to 23%, either due to
18                                              Seroprevalence afterwards was 23.0% (95% CI 17.7, 29.3)
19 Faso, the general population has an antibody seroprevalence against 12 pneumococcal serotypes similar
20                        This study shows high seroprevalence against group A meningococci in Burkina F
21  Supplemental mOPV1 resulted in almost total seroprevalence against poliovirus type 1, which is consi
22 ucted a study in Moradabad in 2007 to assess seroprevalence against poliovirus types 1, 2, and 3 in c
23 cent absence of poliomyelitis cases; whereas seroprevalence against types 2 and 3 was expected for ro
24 Survey (NHANES), we examined HSV-1 and HSV-2 seroprevalence among 14- to 49-year-olds in the United S
25 s detected in poultry, and consequently, the seroprevalence among exposed humans was between 5.6% and
26                                        Lower seroprevalence among groups suggest that they represent
27                                 The baseline seroprevalence among infants aged 6-9 months in 2014 was
28                                  The overall seroprevalence among the sH3N2-primed population against
29 nt associations were found between T. gondii seroprevalence and a history of major depression (n = 57
30 a significant relationship between T. gondii seroprevalence and bipolar disorder type I for responden
31 a showed a striking relationship between age seroprevalence and clinical data, demonstrating the proo
32            The association between H. pylori seroprevalence and colorectal cancer risk was estimated
33    There was no association between baseline seroprevalence and detection of precancer during follow-
34 as demonstrated by the presence of increased seroprevalence and elevated viral loads, but the mechani
35                    To understand prior mumps seroprevalence and factors associated with the presence
36 non-inferiority margin of 10% for poliovirus seroprevalence and measles, rubella, and yellow fever se
37 vitro, hindering efforts to understand their seroprevalence and pathogenicity.
38 on in children and adults to determine HHV-8 seroprevalence and potential routes of transmission.
39                                          The seroprevalence and risk factors identified in this study
40                                              Seroprevalence and seroprotection were defined as an HI
41                     We also investigated the seroprevalence and specificity of GII.4 antibody in the
42                                              Seroprevalence and vaccination coverage data indicate hi
43 stic pathologies mirror the geographic HHV-8 seroprevalence, and certain groups of patients are at hi
44 The factors driving the decline in H. pylori seroprevalence appear to be acting preferentially on the
45 gher in donors living in a high anti-HEV IgG seroprevalence area (1.9% versus 0.7%, P < 0.001) and in
46            Analysis indicated bird and flock seroprevalence as 4.2% (11/262) and 23.1% (9/39), respec
47                  We assessed cytomegalovirus seroprevalence as a risk factor for morbidity and mortal
48 udies are limited by lack of aquaporin-4-IgG seroprevalence assessment, absence of population-based U
49                                       In the seroprevalence assessment, PV type 1 and 3 seroprevalenc
50            Despite substantial reductions in seroprevalence, at least 9% of males were seropositive f
51                                              Seroprevalence before the pandemic was 6.7% (95% CI 5.0,
52 patients were anti-HEV IgG positive with the seroprevalence being highest in those from the Midwest (
53                                        HHV-8 seroprevalence by either assay was 75.4% (95% confidence
54                 Familial dependence in HHV-8 seroprevalence by either assay was found between mother-
55                                     Reported seroprevalence by MN ranged from 0.6% to 9% (median, 2.7
56 here was a significant difference in overall seroprevalence by region: 26.2% in LRR and 17.1% in URR
57                                              Seroprevalence conferred protection against subsequent H
58 rticles were pooled to estimate age-specific seroprevalence curves in 1990 and 2005, and to produce a
59 sic results from epidemiological theory with seroprevalence data and highly spatially resolved data a
60                   Human papillomavirus (HPV) seroprevalence data can help define the epidemiology of
61  Our study also highlights the importance of seroprevalence data for precise quantitative analysis of
62 uito representations, using surveillance and seroprevalence data for several ZIKV outbreaks in Pacifi
63 ata collected over 14 years and longitudinal seroprevalence data from 2010 to 2013.
64 ystematic review, antibody to HCV (anti-HCV) seroprevalence data from 232 articles were pooled to est
65 eak potential, demonstrated using 2006 mumps seroprevalence data from Belgium and Belgian vaccination
66 els, but which is a prominent feature of the seroprevalence data from Paraguay.
67                                              Seroprevalence data reported by the studies ranged from
68                         The age-specific HPV seroprevalence data were best explained by a partner acq
69                     In this age group, HSV-1 seroprevalence declined >29% from 1976-1980 to 2005-2010
70 ong adolescents aged 14-19 years, among whom seroprevalence declined by nearly 23%, from 39.0% to 30.
71           From 1999-2004 to 2005-2010, HSV-1 seroprevalence declined by nearly 7% (P < .01), but HSV-
72 tic models using information on age-specific seroprevalence demonstrated a decrease in the transmissi
73 e declined by nearly 7% (P < .01), but HSV-2 seroprevalence did not change significantly.
74                                Pandemic H1N1 seroprevalence did not vary in relation to ambient tempe
75 % (median, 2.7%), which was greater than the seroprevalence estimated through the WHO-recommended cas
76 ich was not significantly different from the seroprevalence estimated through the WHO-recommended cas
77 and/or in metropolitan areas had the highest seroprevalence estimates.
78                           Remarkably, canine seroprevalence for different HuNoV genotypes mirrored th
79 ity (P = .003) were associated with a higher seroprevalence for genus beta HPV types.
80                                     Baseline seroprevalence for HPV16 L1 was associated with decrease
81    The incidence of PML is very low, whereas seroprevalence for the virus is high, suggesting infecti
82                                        Human seroprevalence for Toxocara antibodies varies with facto
83                                              Seroprevalence for type 1 wild poliovirus was >96.4% for
84                            Between settings, seroprevalences for merozoite antigens were similar betw
85             We also reviewed HSV-1 and HSV-2 seroprevalence from 1976-1980 to 2005-2010.
86                 The largest decline in HSV-1 seroprevalence from 1999-2004 to 2005-2010 was observed
87                               The pooled HCV seroprevalence from all cohorts was 2.98% (95% CI 2.86-3
88 ulation, there was a significant increase in seroprevalence, from 26% (n = 56/215 dogs) on the day of
89 where the epidemic started earlier and adult seroprevalence has been higher, HIV adaptation to HLA in
90 a booster at age 10-14 years decreased HBsAg seroprevalence if participants were born to HBsAg-positi
91                                 We estimated seroprevalence in 1999-2004 and 2005-2010, stratified by
92            We set out to examine age-related seroprevalence in a community where we have previously c
93 ak sample, and near-farm by immunoglobulin M seroprevalence in a municipal population sample.
94 cted infections, was estimated regionwide by seroprevalence in a pre- versus postoutbreak sample, and
95                                 Although HEV seroprevalence in Afghanistan is not known, HEV infectio
96 on was found to significantly decrease HBsAg seroprevalence in childhood through young adulthood and
97 1, 2014, for studies containing data for HCV seroprevalence in different population groups in WHO-def
98 ed efficacy of catch-up vaccination on HBsAg seroprevalence in early adulthood was 21% (95% CI 10%-30
99 s have increased in cattle along with rising seroprevalence in elk.
100                                              Seroprevalence in humans was examined by screening sera
101 egate genetically from Ad5 and exhibit lower seroprevalence in humans, making them attractive vaccine
102   In 2012-2013, we conducted a survey of HPV seroprevalence in males to assess whether or not a herd
103          The findings suggest that lower HPV seroprevalence in older US women primarily reflects coho
104                             The expected HCV seroprevalence in Philadelphia during 2010-2013 was calc
105   The role of putatively protective antibody seroprevalence in preventing pneumococcal meningitis in
106                                 Furthermore, seroprevalence in swine sera from 2006 to 2008 suggested
107 L and there was a significantly higher HBsAg seroprevalence in the HIV cohort, compared to the contro
108 e for different HuNoV genotypes mirrored the seroprevalence in the human population.
109 rsenic was inversely associated with VZV IgG seroprevalence in the U.S.
110 nfluenza by investigating the prevalence and seroprevalence in this potentially vulnerable population
111 00000 with a prevalence of HSV-2 of 16% (the seroprevalence in US adults with unknown symptom status)
112 nclude species and populations with high AIV seroprevalences, in addition to those with high infectio
113 in the Ugandan population-based sample, KSHV seroprevalence increased from 10% among 2-year-old child
114                                        HHV-8 seroprevalence increased from 16% among children aged 1.
115          In the Ugandan clinic-based sample, seroprevalence increased from 9.3% among 2-year-old chil
116                                              Seroprevalence increases with age, but it is not clear i
117                                   Worldwide, seroprevalence is <10% up to 10 years of age, with the e
118 tion is similarly high in males and females, seroprevalence is lower in males.
119                              Cytomegalovirus seroprevalence is not associated with prolonged mechanic
120      In a population-based sample, T. gondii seroprevalence is not elevated in unipolar mood disorder
121 n rates but lack precision in settings where seroprevalence is still high.
122 f transmission settings, as characterised by seroprevalence levels among 9-y-olds (SP9).
123                          Helicobacter pylori seroprevalence levels in US adults participating in the
124                                     Although seroprevalence levels remained similar to those found in
125                   Despite relatively high PV seroprevalence, Namibia might remain at risk for a PV ou
126 herefore not always responsible for the high seroprevalence observed in adults.
127                                          The seroprevalence of 1 cutaneous HPV type was 96% and 90% f
128  Using multiplex serology, we determined the seroprevalence of 10 human PyVs (BK, JC, KI, WU, MCV, HP
129 M+; 4.4% were F+M-, resulting in the overall seroprevalence of 11.4%.
130                      We found an overall IgG seroprevalence of 22.4% (8%-86.4%) depending on the geog
131       For testing a population with an HCVAb seroprevalence of 3.25%, all strategies when adopting qu
132 s 17.8%), while Mexican Americans had higher seroprevalence of 31/33/45/52/58 (23.6% vs 15.9%) (P < .
133 panic whites, non-Hispanic blacks had higher seroprevalence of 31/33/45/52/58 (36.8% vs 15.9%) and 16
134  for HCV (42 648 individuals), with a pooled seroprevalence of 5.73% (95% CI 4.90-6.56).
135 public of Ireland, with an overall estimated seroprevalence of 50% (n = 314/625 dogs).
136 ical patients with a pretransfusion B19V IgG seroprevalence of 78%.
137                                          The seroprevalence of AiV is approximately 60% in children u
138                                              Seroprevalence of all screened AB was comparable in heal
139                                              Seroprevalence of all type categories, especially HPV 31
140                             At baseline, the seroprevalence of anti-A(H5N1) antibodies (titer, >/=80)
141              However, we observed increasing seroprevalence of anti-HBc and isolated anti-HBs when su
142 ence, there is a significant increase in the seroprevalence of anti-HBs, anti-HBc, and HBV DNA, indic
143                             We estimated the seroprevalence of anti-HEV antibody and annual incidence
144                          The low and similar seroprevalence of anti-HEV between the at-risk group and
145           Non-Hispanic blacks had the lowest seroprevalence of anti-HEV immunoglobulin G (15.3%, 95%
146                             We show that the seroprevalence of anti-M2 antibodies increased with age
147                         We then assessed the seroprevalence of antibodies to Ebola virus in a cross-s
148                                          The seroprevalence of antibodies to HEV in US service member
149 objectives of this survey were to assess the seroprevalence of antibodies to poliovirus types 1 and 3
150 s were factors independently associated with seroprevalence of any HPV vaccine type among both female
151 .5% among females and 12.2% among males; the seroprevalence of any HPV vaccine type increased with ag
152             Non-Hispanic blacks had a higher seroprevalence of any HPV vaccine type than that observe
153                                          The seroprevalence of B burgdorferi among patients with uvei
154                                          The seroprevalence of B burgdorferi among uveitis patients w
155               Eligible studies had to report seroprevalence of both hepatitis B surface antigen (HBsA
156                                We found that seroprevalence of Brucella spp. and T. gondii antibodies
157  the need for a greater understanding of the seroprevalence of chlamydial infection in US populations
158                                          The seroprevalence of CMV among the 462 enrolled mothers was
159                                          The seroprevalence of E. histolytica was 33% (14/43) from th
160                                              Seroprevalence of EBV, CMV, herpes simplex virus types 1
161                                  The overall seroprevalence of HBsAg and anti-HBc was significantly l
162                           We recorded a high seroprevalence of HCV across populations of sub-Saharan
163                                   The pooled seroprevalence of HCV was 11.87% (95% CI 7.05-16.70) acr
164 vaccinations, of their effectiveness, and of seroprevalence of hepatitis A antibody and anti-HB surfa
165 ive antiviral therapy, the estimated overall seroprevalence of hepatitis B surface antigen remains hi
166                   In west Africa, the pooled seroprevalence of hepatitis D virus was 7.33% (95% CI 3.
167 tial modes of transmission and determine the seroprevalence of HEV among animal handlers at the insti
168                                          The seroprevalence of HEV in the civilian noninstitutionaliz
169                        The weighted national seroprevalence of HEV in the U.S. is much less than prev
170  for HEV was used, we estimated the weighted seroprevalence of HEV infection among U.S. individuals 6
171                  Based on these results, the seroprevalence of HEV is only one-third as high as previ
172                   Nevertheless, the reported seroprevalence of HEV varies greatly depending on the ge
173                        The weighted national seroprevalence of HEV was 6% (95% confidence interval [C
174  obtained with a high performance assay, the seroprevalence of HEV was estimated at 6.0% in the U.S.
175                                We determined seroprevalence of HPV 6/11/16/18/31/33/45/52/58 among 49
176                            We determined the seroprevalence of HPV types 6, 11, 16, and 18 (HPV types
177                            In 2005-2010, the seroprevalence of HSV-1 was 53.9%, and the seroprevalenc
178 e seroprevalence of HSV-1 was 53.9%, and the seroprevalence of HSV-2 was 15.7%.
179 ssion during coitus and contributing to high seroprevalence of HSV-2 worldwide.
180 e in good agreement with the near-ubiquitous seroprevalence of IDV previously found.
181                     The overall age-adjusted seroprevalence of IgG antibody to mumps virus during 199
182                         In spite of the high seroprevalence of infection, the risk factors that predi
183 ission is primarily responsible for the high seroprevalence of KSHV among adults that is observed thr
184        Compared with the general population, seroprevalence of MERS-CoV antibodies was significantly
185                                              Seroprevalence of MERS-CoV antibodies was significantly
186                             We evaluated the seroprevalence of myelin oligodendrocyte glycoprotein im
187 practices were inversely associated with the seroprevalence of polyomaviruses and herpesviruses.
188                                              Seroprevalence of polyomaviruses ranged from 38.5% to 99
189 owever, limited data exist on the population seroprevalence of PyVs and individual characteristics th
190                                 Age-specific seroprevalence of reference strain SBA titres most likel
191 on to ambient temperature changes, while the seroprevalence of seasonal H3N2 and H1N1 influenza virus
192 c enzyme immunoassay was used to measure the seroprevalence of serum immunoglobulin G (IgG) antibody
193 t schizophrenia is associated with increased seroprevalence of T. gondii, but a possible link of the
194 from A. baumannii, was used to determine the seroprevalence of the K1 capsule in a collection of 100
195                                          The seroprevalence of these novel rhesus monkey adenovirus v
196 usion, the results of this study showed high seroprevalence of toxocariasis among clinically suspecte
197 is, malnutrition was associated with a lower seroprevalence of type 3 antibodies.
198 ated the association between arsenic and the seroprevalence of VZV IgG antibody in a representative s
199                                          The seroprevalence of wild poliovirus types 2 and 3 increase
200                                          The seroprevalence of ZIKV was 6.2% based on ZIKV immunoglob
201                      Hepatitis E virus (HEV) seroprevalences of 0.3%-53% were reported from industria
202                                          The seroprevalences of antibodies to AAV7 and to AAV8 were l
203                                              Seroprevalences of antibodies to poliovirus types 1, 2,
204        Among subjects with 0 tOPV doses, the seroprevalences of antibodies to type 3 were 50%, 77%, a
205                                 Although the seroprevalences of both viruses were low in Finland, our
206                                          The seroprevalences of HPV types 6, 11, 16, and 18 among fem
207                                          The seroprevalences of pandemic H1N1, seasonal H1N1, and H3N
208 rs to be lower than in populations with high seroprevalence, older epidemics, and/or limited HLA dive
209      In a second patient cohort of mixed HIV seroprevalence, plasma PIIINP concentration was increase
210 ub-Saharan Africa and other high HIV and CMV seroprevalence populations globally.
211 isk for a PV outbreak, particularly in lower-seroprevalence populations, such as HIV-positive females
212                                              Seroprevalence pre-alloHSCT was 13%.
213 emonstrating the proof-of-principle that age seroprevalence predicts transmission rates and therefore
214                                  We examined seroprevalence (presence of detectable antibodies in ser
215                           Annual brucellosis seroprevalence ranged from 8.7% (95% CI = 1.8-15.6) to 4
216 s were seropositive for at least 1 PyV, with seroprevalences ranging from 17.6% (HPyV9) to 99.1% (HPy
217 ectional study of 152 U.K. adults, with HCMV seroprevalence rate of 36%, we find that HCMV seropositi
218 antenatal human immunodeficiency virus (HIV) seroprevalence rates ( approximately 30%) with low perin
219 d individuals are needed to establish global seroprevalence rates and potential disease associations.
220                                              Seroprevalence rates and titers of neutralizing antibodi
221                    The primary outcomes were seroprevalence rates for poliovirus 4-6 weeks post-vacci
222 med a systematic review for reports of HBsAg seroprevalence rates in 102 countries (covering PubMed f
223                                          All seroprevalence rates in excess of 60% were found in mari
224                               The decline of seroprevalence recently observed in many countries might
225                      Hepatitis C virus (HCV) seroprevalence remains high in people who inject drug (P
226                                              Seroprevalence rose throughout childhood, from 8% in chi
227 /NMOSD and aquaporin-4-IgG seroincidence and seroprevalence (sera collected in 80-84% of IDD) among p
228  impact of congenital CMV infections in high-seroprevalence settings.
229                                              Seroprevalence should be considered in deciphering patte
230     Wang et al. overinterpret the results of seroprevalence studies and take too little account of un
231                     Poliovirus (PV) antibody seroprevalence studies assess population immunity, verif
232             Representative, population-based seroprevalence studies complement clinical trials and pr
233 t and past ZIKV infections for surveillance, seroprevalence studies, and intervention trials.
234 ections, hence, facilitating epidemiological seroprevalence studies.
235 meningitis belt, we conducted a pneumococcal seroprevalence study during a meningococcal meningitis e
236                                         This seroprevalence study provided extremely useful informati
237                   This was a cross-sectional seroprevalence study using de-identified blood samples a
238                                    An 8-week seroprevalence study was conducted in an urban ED in 201
239                               We conducted a seroprevalence survey among students to assess vaccinati
240  conducted a household-based, age-stratified seroprevalence survey in Bamako, Mali, in 2012, 2 years
241 ng 2011-2014, Nigeria conducted serial polio seroprevalence surveys (SPS) in Kano Metropolitan Area,
242  conducted routine immunization coverage and seroprevalence surveys before and after a September 2007
243                   The results from the polio seroprevalence surveys conducted in Kano Metropolitan Ar
244 tive influenza surveillance and intermittent seroprevalence surveys in a household-based cohort in Vi
245                            We identified 256 seroprevalence surveys in emigrants from 52 countries (i
246 la Mohammed Specialist Hospital (Kano) for 3 seroprevalence surveys.
247 HIV-positive females had significantly lower seroprevalence than HIV-negative females for PV1 (91.8%
248                        We calculated overall seroprevalence through a random effects meta-analysis mo
249 E HSV-1 is an important pathogen with a high seroprevalence throughout the human population.
250 ns than in the general U.S. population, with seroprevalence to H. pylori approaching 75%.
251 y of reported cases, molecular epidemiology, seroprevalence, vaccine coverage, and adequacy of survei
252                        The 2011 study showed seroprevalence values of 81%, 75%, and 73% for polioviru
253            Among children aged 36-47 months, seroprevalence values were greater (91%, 87%, and 85% fo
254                                              Seroprevalence varied among species (highest in eiders (
255                                         cLIA seroprevalence varied with previous exposure; the preval
256                Because of its very low human seroprevalence, vesicular stomatitis virus (VSV) has pro
257      Most humans are immune to Ad5, so lower-seroprevalence viruses like human Ad6 and Ad26 are being
258                 In east and southern Africa, seroprevalence was 0.05% (0.00-1.78) in general populati
259                                  Overall IgM seroprevalence was 1% (0%-4.6%).
260                                       Rodent seroprevalence was 1.4%, with Oligoryzomys longicaudatus
261                                        HIV-1 seroprevalence was 11% (74/655) in children under 15 yea
262                               The pooled HCV seroprevalence was 2.65% (95% CI 2.53-2.78) across all 1
263                                        HHV-8 seroprevalence was 2.8% (29/1023) among blood donors, 7.
264                           In central Africa, seroprevalence was 25.64% (12.09-42.00) in general popul
265 = 1.00 (95% CI = 0.85-1.16) when brucellosis seroprevalence was 30%.
266                For any HPV vaccine type, the seroprevalence was 32.5% among females and 12.2% among m
267                          Human herpesvirus 8 seroprevalence was 4% (10/249) in donors and 18% (93/517
268                   In children 1-9 years old, seroprevalence was 4.4% in LRR and 3.9% in URR.
269    With KIR3DS1 plus HLA-B Bw4-80I, the KSHV seroprevalence was 40% lower (adjusted OR for the combin
270                          Similarly, the KSHV seroprevalence was 40% lower (adjusted OR, 0.6; P = .01)
271                               Among females, seroprevalence was 40.5% for any of the 9 vaccine types,
272                                     Maternal seroprevalence was 61%, birth prevalence was 0.37%, resu
273                                  The overall seroprevalence was 64.0% for AMA-1, 39.5% for MSP-119, a
274                                         KSHV seroprevalence was 7.5%-9.0% among South African childre
275                        HPV 6, 11, 16, and 18 seroprevalence was 8.1%, 13.9%, 12.7%, and 10.8%, respec
276                                          The seroprevalence was 94.6% for PV1, 97.0% for PV2, and 85.
277                                              Seroprevalence was also not associated with poor outcome
278                                              Seroprevalence was compared to the age-specific NmA meni
279 ses regarding anti-HEV and anti-Yersinia IgG seroprevalence was conducted.
280                                              Seroprevalence was higher among US-born non-Hispanic bla
281                           Overall, H. pylori seroprevalence was higher in cases (46.1%) than in contr
282                                              Seroprevalence was highest for HPV types 4 (46%), 1 (37%
283 e seroprevalence assessment, PV type 1 and 3 seroprevalence was lower among women aged 15-29 years in
284                                         cLIA seroprevalence was lower than VLP ELISA, suggesting that
285                                              Seroprevalence was much higher than AIV infection based
286  adjustment for confounding, cytomegalovirus seroprevalence was not associated with the primary outco
287 2013 H3N2v viruses was >50%, and age-related seroprevalence was observed.
288  associations were identified (p</=0.05), AI seroprevalence was positively associated with exposure t
289                                          HIV seroprevalence was remarkably high, ranging from 11%-26%
290                                   The HPgV-2 seroprevalence was significantly higher (P < 0.0001) amo
291                                              Seroprevalence was significantly higher to 2013 H3N2v th
292                                              Seroprevalence was significantly lower in the 1967-1976
293 tively).In 2013, the results showed that the seroprevalence was unexpectedly low among infants aged 6
294                                   Poliovirus seroprevalence was universally high (>97%) after vaccina
295 ional surveys on HBV surface antigen (HBsAg) seroprevalence were conducted in 1996-2000 and 2008-2012
296                  Poliovirus type 1, 2, and 3 seroprevalences were 88% (95% confidence interval [CI],
297                             Among males, the seroprevalences were lower for each type, with 6.3% obse
298 uthors assessed the association of H. pylori seroprevalence with risk of colorectal cancer in a large
299 g persistence of the virus results in a high seroprevalence worldwide and may contribute to age-relat
300  Data on residual infant deaths and maternal seroprevalence would be valuable inputs into considerati

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top